Pichia pastoris Recombinant Proteins Production （毕赤酵母属pastoris重组蛋白的生产）.pdfVIP

B I O P R O C E S S TECHNICAL Production of Humanlike Recombinant Proteins in Pichia pastoris From Expression Vector to Fermentation Strategy Christian Julien ver since Invitrogen of Carlsbad, effective humanlike therapeutic CA () protein manufacturing systems. The acquired the distribution rights goal is to achieve high fermentation Ein 1993 for the Pichia pastoris yields in processes that extend for yeast protein expression system, days instead of the weeks required P. pastoris has gained widespread for mammalian expression systems. popularity, as witnessed by an Today the P. pastoris system is licensed increasing number of publications to more than 160 companies in the (Figure 1). The expression system was biotechnology, pharmaceutical, originally developed as a single-cell vaccine, animal health, and food protein production platform by Philips industries. More than 500 Photo 1 JAMES CREGG, KECK GRADUATE INSTITUTE, Petroleum of Bartlesville, OK, and heterologous proteins have been CLAREMONT CA (WWW.KGI.EDU) later adapted for heterologous protein expressed in this host (3, 4). expression (1, 2). It is freely distributed The first of those proteins entered references 7–17 are called out in among academic research laboratories, human clinical trials in 1996, followed Table 2). The dosage/vial of 12.5 g is although its use for commercial by an increasing number of candidate extremely high compared with other production requires a license from therapeutic proteins and antigens (5). biopharmaceuticals and truly represents the current patent holder, Research All yeast-based